ACOTEC-B(06669) released its mid-term financial performance with a net profit of 88.577 million yuan, representing a year-on-year increase of 121.7%.
Sino Biopharmaceutical Limited (06669) released its performance for the six months ending on June 30, 2025. During the period, the group achieved...
ACOTEC-B (06669) released its performance for the six months ending June 30, 2025. The group made a revenue of 351 million RMB during the period, an increase of 20.1% compared to the previous year. The net profit for the period was 88.577 million RMB, a 121.7% increase compared to the previous year. The basic earnings per share was 0.29 RMB.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
